<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755023</url>
  </required_header>
  <id_info>
    <org_study_id>2004-30</org_study_id>
    <nct_id>NCT04755023</nct_id>
  </id_info>
  <brief_title>Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis</brief_title>
  <acronym>TEMOBIC</acronym>
  <official_title>Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first-line treatment of anaplastic oligodendrogliomas, radiotherapy exclusive or combined&#xD;
      with PCV, will be defined by the pending results of phase III of the EORTC.&#xD;
&#xD;
      If the phase II study proposed here achieves its objective, it may help define a new&#xD;
      treatment regimen that will be compared to the standard arm from phase III of the EORTC.&#xD;
&#xD;
      In addition, this study, by prospectively testing the predictive value of 1p and 19q&#xD;
      deletions and of REGF amplification, may allow characterization of patients using these&#xD;
      markers. If validated, this characterization can constitute a key element in any therapeutic&#xD;
      evaluation (patient stratification), and potentially a major tool for medical decision&#xD;
      support in these tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2005</start_date>
  <completion_date type="Actual">December 15, 2010</completion_date>
  <primary_completion_date type="Actual">March 15, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate of the BCNU-TMZ combination administered before radiotherapy</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 28 days)</time_frame>
    <description>In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate of the BCNU-TMZ combination administered before radiotherapy</measure>
    <time_frame>At the end of Cycle 4 (each cycle is 28 days)</time_frame>
    <description>In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate of the BCNU-TMZ combination administered before radiotherapy</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 28 days)</time_frame>
    <description>In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate of the BCNU-TMZ combination administered before radiotherapy</measure>
    <time_frame>1 month after radiotherapy</time_frame>
    <description>In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Oligodendroglioma; Oligoastrocytoma</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 6 cycles of chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide</intervention_name>
    <description>Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven oligodendroglioma or anaplastic oligoastrocytoma, newly&#xD;
             diagnosed, resulting or not from a low grade glioma&#xD;
&#xD;
          -  Tumor with measurable contrast enhancement (at least 15 mm in diameter)&#xD;
&#xD;
          -  Surgical procedure limited to a biopsy or partial excision&#xD;
&#xD;
          -  In the event of partial excision, an early postoperative check-up (&lt;72 hours)&#xD;
             performed at best by MRI, if not by CT, is required.&#xD;
&#xD;
          -  Time between surgery and inclusion less than or equal to one and a half months (45&#xD;
             days)&#xD;
&#xD;
          -  Age&gt; 18 years old; &lt;70&#xD;
&#xD;
          -  Karnofsky index&gt; 60&#xD;
&#xD;
          -  Stable or reduced dose of corticosteroids in the 15 days prior to inclusion&#xD;
&#xD;
          -  Polynuclear neutrophils&gt; 1500; platelets&gt; 100,000&#xD;
&#xD;
          -  Bilirubin &lt;1.25 x UNL; SGOT, SGPT, PAL &lt;2.5 x UNL&#xD;
&#xD;
          -  Absence of serious uncontrolled pathology&#xD;
&#xD;
          -  Patient having received and understood the information and having signed the consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of GBM foci within the tumor&#xD;
&#xD;
          -  Absence of evaluable residue after surgery&#xD;
&#xD;
          -  Previous chemotherapy or radiotherapy&#xD;
&#xD;
          -  Unsatisfactory expected monitoring conditions&#xD;
&#xD;
          -  Pregnant or breastfeeding woman; lack of effective contraception if of childbearing&#xD;
             age&#xD;
&#xD;
          -  History of malignant disease (with the exception of CIS of the cervix and basal cell&#xD;
             cancer)&#xD;
&#xD;
          -  Contraindications related to the examination of the I.R.M.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assistance Publique - HÃ´pitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>BCNU-Temozolomide</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

